
Marco Gobbi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7666991/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Surface Plasmon Resonance-Based Assay for Simultaneous Measurement of Concentrations of and Anti-Drug. Methods in Molecular Biology, 2022, 2313, 323-336.	0.9	0
2	High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. International Journal of Antimicrobial Agents, 2022, 59, 106516.	2.5	32
3	New nanostructures inhibiting human mannose binding lectin identified by a novel surface plasmon resonance assay. Sensors and Actuators B: Chemical, 2022, 360, 131661.	7.8	0
4	Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. Cell Death and Disease, 2022, 13, .	6.3	9
5	A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis. Applied Sciences (Switzerland), 2022, 12, 6102.	2.5	0
6	Nonphosphorylated tau slows down Al̂²1–42 aggregation, binds to Al̂²1–42 oligomers, and reduces Al̂²1–4 toxicity. Journal of Biological Chemistry, 2021, 296, 100664.	12 3.4	3
7	The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions. Oncogene, 2021, 40, 1721-1736.	5.9	31
8	Characterization of the neutralizing antiâ€emicizumab antibody in a patient with hemophilia A and inhibitor. Journal of Thrombosis and Haemostasis, 2021, 19, 711-718.	3.8	19
9	Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS. Critical Care, 2021, 25, 113.	5.8	36
10	Plasma-derived and recombinant C1 esterase inhibitor: Binding profiles and neuroprotective properties in brain ischemia/reperfusion injury. Brain, Behavior, and Immunity, 2021, 93, 299-311.	4.1	10
11	Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?. Biomolecules, 2021, 11, 855.	4.0	23
12	Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera. Scientific Reports, 2021, 11, 14976.	3.3	7
13	Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity. Viruses, 2021, 13, 1745.	3.3	2
14	Doxycycline rescues recognition memory and circadian motor rhythmicity but does not prevent terminal disease in fatal familial insomnia mice. Neurobiology of Disease, 2021, 158, 105455.	4.4	4
15	The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines. Nature Nanotechnology, 2021, 16, 1169-1171.	31.5	48
16	Brain Kynurenine Pathway and Functional Outcome of Rats Resuscitated From Cardiac Arrest. Journal of the American Heart Association, 2021, 10, e021071.	3.7	2
17	A novel hotspot of gelsolin instability triggers an alternative mechanism of amyloid aggregation. Computational and Structural Biotechnology Journal, 2021, 19, 6355-6365.	4.1	2
18	Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease. ACS Chemical Neuroscience, 2020, 11, 367-372.	3.5	22

Marco Gobbi

#	Article	IF	CITATIONS
19	Control of Complement Activation by the Long Pentraxin PTX3: Implications in Age-Related Macular Degeneration. Frontiers in Pharmacology, 2020, 11, 591908.	3.5	11
20	Ventilation With Argon Improves Survival With Good Neurological Recovery After Prolonged Untreated Cardiac Arrest in Pigs. Journal of the American Heart Association, 2020, 9, e016494.	3.7	15
21	A portable optical-fibre-based surface plasmon resonance biosensor for the detection of therapeutic antibodies in human serum. Scientific Reports, 2020, 10, 11154.	3.3	82
22	The Anti-Amyloidogenic Action of Doxycycline: A Molecular Dynamics Study on the Interaction with Aβ42. International Journal of Molecular Sciences, 2019, 20, 4641.	4.1	28
23	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. Scientific Reports, 2019, 9, 2064.	3.3	53
24	Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. Brain, 2019, 142, 249-254.	7.6	38
25	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 32-40.	2.5	46
26	Brain disposition, metabolism and behavioral effects of the synthetic opioid AH-7921 in rats. Neuropharmacology, 2018, 133, 51-62.	4.1	5
27	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. Neurobiology of Aging, 2018, 70, 128-139.	3.1	52
28	Pharmacological inhibition of mannose-binding lectin ameliorates neurobehavioral dysfunction following experimental traumatic brain injury. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 938-950.	4.3	35
29	Fingolimod Limits Acute Aβ Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal Neurons. Scientific Reports, 2017, 7, 41734.	3.3	27
30	Brain Disposition of cis-para-Methyl-4-Methylaminorex (cis-4,4′-DMAR) and Its Potential Metabolites after Acute and Chronic Treatment in Rats: Correlation with Central Behavioral Effects. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 492-500.	2.5	4
31	QSAR model for blood-brain barrier permeation. Journal of Pharmacological and Toxicological Methods, 2017, 88, 7-18.	0.7	33
32	Humanin Specifically Interacts with Amyloid-β Oligomers and Counteracts Their in vivo Toxicity. Journal of Alzheimer's Disease, 2017, 57, 857-871.	2.6	23
33	Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Biochemical Pharmacology, 2017, 144, 52-62.	4.4	11
34	A validated, sensitive HPLCâ€MS/MS method for quantification of <i>cisâ€para</i> â€methylâ€4â€methylaminore (<i>cis</i> â€4,4'â€DMAR) in rat and human plasma: application to pharmacokinetic studies in rats. Drug Testing and Analysis, 2017, 9, 870-879.	2.6	7
35	An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein. PLoS ONE, 2017, 12, e0182589.	2.5	19
36	Utilization of the Monte Carlo Method to Build up QSAR Models for Hemolysis and Cytotoxicity of Antimicrobial Peptides. Current Drug Discovery Technologies, 2017, 14, 229-243.	1.2	17

#	Article	IF	CITATIONS
37	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers. Journal of Alzheimer's Disease, 2016, 53, 1485-1497.	2.6	12
38	A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein. Scientific Reports, 2016, 6, 23180.	3.3	34
39	Scaffold Optimisation of Tetravalent Antagonists of the Mannose Binding Lectin. Chemistry - A European Journal, 2016, 22, 3686-3691.	3.3	7
40	A New Surface Plasmon Resonance Assay for In Vitro Screening of Mannose-Binding Lectin Inhibitors. Journal of Biomolecular Screening, 2016, 21, 749-757.	2.6	9
41	Monte Carlo method for predicting of cardiac toxicity: hERG blocker compounds. Toxicology Letters, 2016, 250-251, 42-46.	0.8	31
42	Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model. Nano Research, 2016, 9, 2190-2201.	10.4	13
43	The new β amyloid-derived peptide Aβ1–6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity. Neurobiology of Disease, 2016, 88, 75-84.	4.4	17
44	Clusterin Binds to Aβ1–42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation. Journal of Biological Chemistry, 2016, 291, 6958-6966.	3.4	99
45	Exposing native cyprinid (Barbus plebejus) juveniles to river sediments leads to gonadal alterations, genotoxic effects and thyroid disruption. Aquatic Toxicology, 2015, 169, 223-239.	4.0	11
46	Brain Uptake of Tetrahydrohyperforin and Potential Metabolites after Repeated Dosing in Mice. Journal of Natural Products, 2015, 78, 2029-2035.	3.0	3
47	A New Surface Plasmon Resonance-Based Immunoassay for Rapid, Reproducible and Sensitive Quantification of Pentraxin-3 in Human Plasma. Sensors, 2014, 14, 10864-10875.	3.8	16
48	Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. Cardiovascular Research, 2014, 104, 37-48.	3.8	42
49	Early Activation of the Kynurenine Pathway Predicts Early Death and Longâ€term Outcome in Patients Resuscitated From Outâ€ofâ€Hospital Cardiac Arrest. Journal of the American Heart Association, 2014, 3, .	3.7	34
50	Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 150-158.	10.2	157
51	Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from out-of-hospital cardiac arrest. Resuscitation, 2014, 85, S13.	3.0	2
52	Expression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity. Neurobiology of Disease, 2014, 62, 521-532.	4.4	30
53	Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest. Heart Rhythm, 2014, 11, 1641-1647.	0.7	9
54	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. Neuropharmacology, 2014, 85, 206-214.	4.1	21

#	Article	IF	CITATIONS
55	6-Methoxy-7-benzofuranoxy and 6-Methoxy-7-indolyloxy Analogues of 2-[2-(2,6-Dimethoxyphenoxy)ethyl]aminomethyl-1,4-benzodioxane (WB4101):1 Discovery of a Potent and Selective α _{1D} -Adrenoceptor Antagonist. Journal of Medicinal Chemistry, 2013, 56, 6402-6412.	6.4	25
56	Selective Nanovector Mediated Treatment of Activated Proinflammatory Microglia/Macrophages in Spinal Cord Injury. ACS Nano, 2013, 7, 9881-9895.	14.6	136
57	New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: The role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome. European Journal of Cancer, 2013, 49, 1491-1500.	2.8	14
58	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 173-178.	3.0	24
59	The GTPase-Activating Protein RN-tre Controls Focal Adhesion Turnover and Cell Migration. Current Biology, 2013, 23, 2355-2364.	3.9	42
60	Novel approaches for studying amyloidogenic peptides/proteins. Current Opinion in Pharmacology, 2013, 13, 797-801.	3.5	15
61	Pharmacology in the high tech age—new developments, opportunities and limitations. Current Opinion in Pharmacology, 2013, 13, 775-777.	3.5	0
62	Tetrahydro-β-carboline-Based Spirocyclic Lactam as Type Il′ β-Turn: Application to the Synthesis and Biological Evaluation of Somatostatine Mimetics. Journal of Organic Chemistry, 2013, 78, 2600-2610.	3.2	19
63	Epitope scanning indicates structural differences in brain-derived monomeric and aggregated mutant prion proteins related to genetic prion diseases. Biochemical Journal, 2013, 454, 417-425.	3.7	12
64	An N-terminal Fragment of the Prion Protein Binds to Amyloid-β Oligomers and Inhibits Their Neurotoxicity in Vivo. Journal of Biological Chemistry, 2013, 288, 7857-7866.	3.4	162
65	A Mouse Model of Familial ALS Has Increased CNS Levels of Endogenous Ubiquinol9/10 and Does Not Benefit from Exogenous Administration of Ubiquinol10. PLoS ONE, 2013, 8, e69540.	2.5	14
66	Functionalization with TAT-Peptide Enhances Blood-Brain Barrier Crossing In vitro of Nanoliposomes Carrying a Curcumin-Derivative to Bind Amyloid-Î' Peptide. Journal of Nanomedicine & Nanotechnology, 2013, 04, .	1.1	31
67	Applications of Surface Plasmon Resonance (SPR) for the Characterization of Nanoparticles Developed for Biomedical Purposes. Sensors, 2012, 12, 16420-16432.	3.8	59
68	Targeting Mannose-Binding Lectin Confers Long-Lasting Protection With a Surprisingly Wide Therapeutic Window in Cerebral Ischemia. Circulation, 2012, 126, 1484-1494.	1.6	119
69	Mutant PrP Suppresses Clutamatergic Neurotransmission in Cerebellar Granule Neurons by Impairing Membrane Delivery of VGCC α2δ-1 Subunit. Neuron, 2012, 74, 300-313.	8.1	64
70	PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Toward Engineering of Functional Nanomedicines for Alzheimer's Disease. ACS Nano, 2012, 6, 5897-5908.	14.6	164
71	Specific Recognition of Biologically Active Amyloid-β Oligomers by a New Surface Plasmon Resonance-based Immunoassay and an in Vivo Assay in Caenorhabditis elegans. Journal of Biological Chemistry, 2012, 287, 27796-27805.	3.4	52
72	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 34-36.	3.0	184

#	Article	IF	CITATIONS
73	A novel spirocyclic tropanyl-Δ2-isoxazoline derivative enhances citalopram and paroxetine binding to serotonin transporters as well as serotonin uptake. Bioorganic and Medicinal Chemistry, 2012, 20, 6344-6355.	3.0	7
74	Affinity and activity profiling of unichiral 8-substituted 1,4-benzodioxane analogues of WB4101 reveals a potent and selective α1B-adrenoceptor antagonist. European Journal of Medicinal Chemistry, 2012, 58, 184-191.	5.5	21
75	Good gene, bad gene: New APP variant may be both. Progress in Neurobiology, 2012, 99, 281-292.	5.7	31
76	Versatile and Efficient Targeting Using a Single Nanoparticulate Platform: Application to Cancer and Alzheimer's Disease. ACS Nano, 2012, 6, 5866-5879.	14.6	127
77	In-vivo (+)-[3H]Fenfluramine Binding to Rat Brain: Biochemical and Autoradiographic Studies. Journal of Pharmacy and Pharmacology, 2011, 41, 253-256.	2.4	11
78	Increased number of brain benzodiazepine receptors after in-vivo administration of estazolam to rats. Journal of Pharmacy and Pharmacology, 2011, 36, 621-622.	2.4	5
79	Biochemical Characterization of a New Highly Cardioselective β-Adrenoceptor Antagonist. Journal of Pharmacy and Pharmacology, 2011, 40, 243-246.	2.4	4
80	Further Studies on α2-Adrenoceptor Subtypes Involved in the Modulation of [3H]Noradrenaline and [3H]5-Hydroxytryptamine Release from Rat Brain Cortex Synaptosomes. Journal of Pharmacy and Pharmacology, 2011, 45, 811-814.	2.4	14
81	Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials, 2011, 32, 1635-1645.	11.4	198
82	Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Al̂21–42 peptide, synthesized by depsi-peptide technique. Biosensors and Bioelectronics, 2011, 26, 2772-2775.	10.1	36
83	A modified protocol to prepare seed-free starting solutions of amyloid-l̂² (Al̂²)1–40 and Al̂²1–42 from the corresponding depsipeptides. Analytical Biochemistry, 2011, 411, 297-299.	2.4	38
84	The binding affinity of anti-Aβ1-42ÂMAb-decorated nanoliposomes to Aβ1-42Âpeptides inÂvitro and to amyloid deposits in post-mortem tissue. Biomaterials, 2011, 32, 5489-5497.	11.4	76
85	Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiology of Disease, 2011, 43, 507-515.	4.4	91
86	Diazepam and desmethyldiazepam differ in their affinities and efficacies at †central' and †peripheral' benzodiazepine receptors. Journal of Pharmacy and Pharmacology, 2011, 39, 388-391.	2.4	29
87	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	220
88	Nanoparticles against Alzheimer's disease: PEG–PACA nanoparticles are able to link the aβ-peptide and influence its aggregation kinetic. Journal of Controlled Release, 2010, 148, e112-e113.	9.9	12
89	Preparation and characterization of lipid-based nanoparticles binding with high affinity amyloid-β1-42 peptide. Journal of Biotechnology, 2010, 150, 27-27.	3.8	2
90	Lipid-based nanoparticles with high binding affinity for amyloid-β1–42 peptide. Biomaterials, 2010, 31, 6519-6529.	11.4	190

#	Article	IF	CITATIONS
91	Functional analysis of a murine monoclonal antibody against the repetitive region of the fibronectin-binding adhesins fibronectin-binding protein A and fibronectin-binding protein B from Staphylococcus aureus. FEBS Journal, 2010, 277, 4490-4505.	4.7	7
92	Regulation of leukocyte recruitment by the long pentraxin PTX3. Nature Immunology, 2010, 11, 328-334.	14.5	396
93	Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. Journal of Biological Chemistry, 2010, 285, 8733-8742.	3.4	70
94	Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2295-2300.	7.1	435
95	New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid-β Peptide. Analytical Chemistry, 2010, 82, 10083-10089.	6.5	50
96	Development of a Proteolytically Stable Retro-Inverso Peptide Inhibitor of β-Amyloid Oligomerization as a Potential Novel Treatment for Alzheimer's Disease. Biochemistry, 2010, 49, 3261-3272.	2.5	139
97	Recombinant C1 inhibitor in brain ischemic injury. Annals of Neurology, 2009, 66, 332-342.	5.3	107
98	Synthesis of new β- and γ-benzyloxy-S-glutamic acid derivatives and evaluation of their activity as inhibitors of excitatory amino acid transporters. Tetrahedron, 2009, 65, 6083-6089.	1.9	17
99	A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis. Science, 2009, 323, 1473-1477.	12.6	357
100	St. Johns Wort Components and the Brain: Uptake, Concentrations Reached and the Mechanisms Underlying Pharmacological Effects. Current Drug Metabolism, 2009, 10, 1055-1065.	1.2	26
101	Immunopurification of Pathological Prion Protein Aggregates. PLoS ONE, 2009, 4, e7816.	2.5	17
102	Synthesis of enantiomerically pure HIP-A and HIP-B and investigation of their activity as inhibitors of excitatory amino acid transporters. Tetrahedron: Asymmetry, 2008, 19, 867-875.	1.8	22
103	<i>N</i> , <i>N</i> â€dimethylâ€thioamphetamine and methylâ€thioamphetamine, two nonâ€neurotoxic substrates of 5â€HT transporters, have scant <i>in vitro</i> efficacy for the induction of transporterâ€mediated 5â€HT release and currents. Journal of Neurochemistry, 2008, 105, 1770-1780.	3.9	19
104	Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. European Journal of Pharmacology, 2008, 578, 171-176.	3.5	205
105	Conformational Plasticity of the Gerstmann–Strässler–Scheinker Disease Peptide as Indicated by Its Multiple Aggregation Pathways. Journal of Molecular Biology, 2008, 381, 1349-1361.	4.2	56
106	Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain, 2008, 131, 1506-1515.	7.6	146
107	Neuroprotective Effects of the Novel Glutamate Transporter Inhibitor (–)-3-Hydroxy-4,5,6,6 <i>a</i> -tetrahydro-3 <i>aH</i> -pyrrolo[3,4- <i>d</i>]-isoxazole-4-carboxylic Acid, Which Preferentially Inhibits Reverse Transport (Glutamate Release) Compared with Glutamate Reuptake, Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 646-656.	2.5	36
108	Gene therapy in epilepsy: The focus on NPY. Peptides, 2007, 28, 377-383.	2.4	62

Marco Gobbi

#	Article	IF	CITATIONS
109	WB4101-Related Compounds:  New, Subtype-Selective α1-Adrenoreceptor Antagonists (or Inverse) Tj ETQq1	1 0.7843 6.4	14 rgBT /O
110	QSAR study forÂaÂnovel series ofÂortho disubstituted phenoxy analogues ofÂα1-adrenoceptor antagonist WB4101. European Journal of Medicinal Chemistry, 2006, 41, 1025-1040.	5.5	24
111	Gerstmann-Strässler-Scheinker Disease Amyloid Protein Polymerizes According to the "Dock-and-Lock―Model. Journal of Biological Chemistry, 2006, 281, 843-849.	3.4	33
112	QSAR study for a novel series of ortho monosubstituted phenoxy analogues of $\hat{I}\pm 1$ -adrenoceptor antagonist WB4101. Bioorganic and Medicinal Chemistry, 2005, 13, 2547-2559.	3.0	26
113	Neuropeptide Y and Its Receptors in Kindling Epileptogenesis. , 2005, , 249-261.		0
114	Antiepileptic Effects of Botulinum Neurotoxin E. Journal of Neuroscience, 2005, 25, 1943-1951.	3.6	87
115	St. John's Wort and its active principles in depression and anxiety — A critical analysis of receptor binding studies. , 2005, , 21-29.		0
116	Potential antidepressant properties of IDN 5491 (hyperforin-trimethoxybenzoate), a semisynthetic ester of hyperforin. European Neuropsychopharmacology, 2005, 15, 211-218.	0.7	16
117	Neuropeptide Y Y5 receptors inhibit kindling acquisition in rats. Regulatory Peptides, 2005, 125, 79-83.	1.9	19
118	In VitroEffects of the Dicyclohexylammonium Salt of Hyperforin on Interleukin-6 Release in Different Experimental Models. Planta Medica, 2004, 70, 680-682.	1.3	17
119	Differential Recognition and Scavenging of Native and Truncated Macrophage-Derived Chemokine (Macrophage-Derived Chemokine/CC Chemokine Ligand 22) by the D6 Decoy Receptor. Journal of Immunology, 2004, 172, 4972-4976.	0.8	132
120	Structure–affinity studies for a novel series of homochiral naphtho and tetrahydronaphtho analogues of α1 antagonist WB-4101. Bioorganic and Medicinal Chemistry, 2004, 12, 4937-4951.	3.0	38
121	The antidepressant mechanism of Hypericum perforatum. Life Sciences, 2004, 75, 1021-1021.	4.3	0
122	The antidepressant mechanism of Hypericum perforatum. Life Sciences, 2004, 75, 1021-1027.	4.3	132
123	Substrate inhibitors and blockers of excitatory amino acid transporters in the treatment of neurodegeneration: critical considerations. European Journal of Pharmacology, 2003, 479, 291-296.	3.5	18
124	Cutting Edge: Scavenging of Inflammatory CC Chemokines by the Promiscuous Putatively Silent Chemokine Receptor D6. Journal of Immunology, 2003, 170, 2279-2282.	0.8	181
125	Appraisal of the Role of Angiotensin II and Aldosterone in Ventricular Myocyte Apoptosis in Adult Normotensive Rat. Journal of Molecular and Cellular Cardiology, 2002, 34, 1655-1665.	1.9	70
126	Hyperforin does not inhibit brain serotonin uptake for inducing antidepressant-like activity in rats. European Neuropsychopharmacology, 2002, 12, 198-199.	0.7	2

#	Article	IF	CITATIONS
127	Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience, 2002, 110, 237-243.	2.3	90
128	Overexpression of S100? in transgenic mice does not protect from serotonergic denervation induced by 5,7-dihydroxytryptamine. Journal of Neuroscience Research, 2002, 67, 501-510.	2.9	3
129	p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers inâ€∫vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings inâ€∫vitro. Journal of Neurochemistry, 2002, 82, 1435-1443.	3.9	41
130	ls St John's wort a â€~Prozac-like' herbal antidepressant?. Trends in Pharmacological Sciences, 2001, 22, 557-559.	8.7	21
131	Chronic treatment with desipramine facilitates its effect on extracellular noradrenaline in the rat hippocampus: studies on the role of presynaptic α 2 -adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 66-72.	3.0	52
132	Autoradiographic Reevaluation of the Binding Properties of 125I-[Leu31,Pro34]Peptide YY and 125I-Peptide YY3-36 to Neuropeptide Y Receptor Subtypes in Rat Forebrain. Journal of Neurochemistry, 2001, 72, 1663-1670.	3.9	12
133	In Vitro Binding Studies with Two Hypericum Perforatum Extracts - Hyperforin, Hypericin and Biapigenin - on 5-HT6, 5-HT7, GABAA/Benzodiazepine, Sigma, NPY-Y1 /Y2 Receptors and Dopamine Transporters. Pharmacopsychiatry, 2001, 34, 45-48.	3.3	97
134	St John's Wort and Literature Quotations. Archives of Internal Medicine, 2001, 161, 1016-a-1017.	3.8	2
135	Plastic Changes in Neuropeptide Y Receptor Subtypes in Experimental Models of Limbic Seizures. Epilepsia, 2000, 41, S115-S121.	5.1	44
136	Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain. Neuroscience Letters, 2000, 292, 49-53.	2.1	16
137	Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 360, 262-269.	3.0	73
138	Release studies with rat brain cortical synaptosomes indicate that tramadol is a 5-hydroxytryptamine uptake blocker and not a 5-hydroxytryptamine releaser. European Journal of Pharmacology, 1999, 370, 23-26.	3.5	21
139	Oleamide-mediated sleep induction does not depend on perturbation of membrane homeoviscosity. FEBS Letters, 1999, 463, 281-284.	2.8	10
140	In vitro studies on the mechanism by which (+)-norfenfluramine induces serotonin and dopamine release from the vesicular storage pool. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 358, 323-327.	3.0	12
141	Distinct Changes in Peptide YY Binding to, and mRNA Levels of, Y1 and Y2 Receptors in the Rat Hippocampus Associated with Kindling Epileptogenesis. Journal of Neurochemistry, 1998, 70, 1615-1622.	3.9	70
142	Somatostatin-and Neuropeptide Y-Mediated Neurotransmission in Kindling Epileptogenesis. Advances in Behavioral Biology, 1998, , 313-325.	0.2	2
143	Carrier-mediated Serotonin Release Induced by d-Fenfluramine: Studies with Human Neuroblastoma Cells Transfected with a Rat Serotonin Transporter. Neuropharmacology, 1997, 36, 803-809.	4.1	14
144	5-HT 3 SEROTONIN HETERO-RECEPTORS INHIBIT [3 H]ACETHYLCHOLINE RELEASE IN RAT CORTICAL SYNAPTOSOMES. Pharmacological Research, 1997, 35, 351-354.	7.1	27

#	Article	IF	CITATIONS
145	FURTHER EVIDENCE OF Ca2+-DEPENDENT, EXOCYTOTIC-LIKE SEROTONIN RELEASE INDUCED BYD-FENFLURAMINE. Pharmacological Research, 1997, 35, 439-442.	7.1	10
146	[3H]5-HT Binding to 5-HT1nonA-nonBReceptors in Rat Hypothalamus Is Not Representative of 5-HT7Receptors. Annals of the New York Academy of Sciences, 1997, 812, 167-168.	3.8	0
147	Carrierâ€dependent and Ca ²⁺ â€dependent 5â€HT and dopamine release induced by (+)â€amphetamine, 3,4â€methylendioxyâ€methamphetamine, <i>p</i> â€chloroamphetamine and (+)â€fenflurar British Journal of Pharmacology, 1997, 121, 1735-1743.	ท เฮ.ศ.	155
148	Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 22-28.	3.0	63
149	Autoradiographic analysis of neuropeptide Y receptor binding sites in the rat hippocampus after kainic acid-induced limbic seizures. Neuroscience, 1996, 70, 47-55.	2.3	70
150	ROLE OF TRANSGLUTAMINASE IN [3H]5-HT RELEASE FROM SYNAPTOSOMES AND IN THE INHIBITORY EFFECT OF TETANUS TOXIN. Neurochemistry International, 1996, 29, 129-134.	3.8	7
151	Effects of repeated oral doses of dexnorfenfluramine on 5-HT levels and 5-HT uptake sites in rat brain. Neuroscience Letters, 1996, 219, 5-8.	2.1	2
152	Cellular localization of neuropeptide-Y receptors in the rat hippocampus. NeuroReport, 1996, 7, 1475-1480.	1.2	18
153	In vivo and in vitro interaction of flunarizine with ?-fenfluramine serotonergic effects. Pharmacology Biochemistry and Behavior, 1996, 53, 155-161.	2.9	8
154	Down-regulation of rat brain 5-HT uptake carriers after treatment with high doses of d-fenfluramine. Brain Research, 1996, 730, 165-172.	2.2	8
155	In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 353, 641-647.	3.0	19
156	<i>p</i> â€Chlorophenylalanine Changes Serotonin Transporter mRNA Levels and Expression of the Gene Product. Journal of Neurochemistry, 1996, 67, 463-472.	3.9	52
157	Down-regulation of rat brain 5-HT uptake carriers after treatment with high doses of ?-fenfluramine. Brain Research, 1996, 730, 165-172.	2.2	4
158	Effects of fluoxetine on basal and K+-induced tritium release from synaptosomes preloaded with [3H]serotonin. Life Sciences, 1995, 56, 785-791.	4.3	7
159	Differential effects of 5,7-dihydroxytryptamine-induced serotoninergic degeneration on 5-HT1A receptors and 5-HT uptake sites in the rat brain. Journal of Chemical Neuroanatomy, 1994, 7, 65-73.	2.1	21
160	Involvement of P-type Ca2+ channels in the K+- and d-fenfluramine-induced [3H]5-HT release from rat hippocampal synaptosomes. Neuropharmacology, 1994, 33, 833-835.	4.1	16
161	Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 306-312.	3.0	17
162	Acute noise stress reduces [3H]5-hydroxytryptamine uptake in rat brain synaptosomes: protective effects of buspirone and tianeptine. European Journal of Pharmacology, 1993, 241, 255-260.	3.5	25

#	Article	IF	CITATIONS
163	Evidence of an exocytotic-like release of [3H]5-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes. European Journal of Pharmacology, 1993, 238, 9-17.	3.5	40
164	The Ca2+-dependent release of serotonin induced by d-fenfluramine involves the P-type Ca2+ channels and protein kinase C activation. European Neuropsychopharmacology, 1993, 3, 439-440.	0.7	0
165	Tetanus toxin inhibits depolarization-induced [3H]serotonin release from rat brain cortex synaptosomes. Neuroscience Letters, 1993, 151, 205-208.	2.1	8
166	Neurochemical effects of tianeptine on stress mechanisms. European Neuropsychopharmacology, 1993, 3, 352.	0.7	0
167	Releasing activities of d-fenfluramine and fluoxetine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin. Naunyn-Schmiedeberg's Archives of Pharmacology, 1992, 345, 1-6.	3.0	62
168	Diazepam binding inhibitor (DBI) increases after acute stress in rat. Neuropharmacology, 1991, 30, 1445-1452.	4.1	52
169	Effect of acute and chronic administration of buspirone on serotonin and benzodiazepine receptor subtypes in the rat brain: An autoradiographic study. Neuropharmacology, 1991, 30, 313-321.	4.1	28
170	Acute noise stress in rats increases the levels of diazepam binding inhibitor (DBI) in hippocampus and adrenal gland. Psychopharmacology, 1991, 103, 339-342.	3.1	29
171	The modulation of [3H]noradrenaline and [3H]serotonin release from rat brain synaptosomes is not mediated by the ?2B-adrenoceptor subtype. Naunyn-Schmiedeberg's Archives of Pharmacology, 1990, 342, 382-6.	3.0	33
172	Regional distribution of low-affinity GABA receptors coupled to benzodiazepine receptor subtypes in rat brain: an autoradiographic evaluation. European Journal of Pharmacology, 1990, 189, 143-148.	2.6	20
173	Autoradiographic localization of [3H]paroxetine specific binding in the rat brain. Neurochemistry International, 1990, 16, 247-251.	3.8	18
174	Alpha-2 adrenoceptors modulating [3H]noradrenaline release in rat brain cortex are not identical to alpha-2B subtype. Pharmacological Research, 1990, 22, 37-38.	7.1	0
175	Changes of specific atrial granules induced by doxorubicin in dog's heart. Pharmacological Research, 1990, 22, 37-38.	7.1	25
176	Antagonist properties of 1-(2-pyrimidinyl) piperazine at presynaptic α2-adrenoceptors in the rat brain. European Journal of Pharmacology, 1990, 180, 183-186.	3.5	26
177	Profile of in vitro binding affinities of neuroleptics at different rat brain receptors: cluster analysis comparison with pharmacological and clinical profiles. Pharmaceutical Research, 1989, 06, 571-577.	3.5	18
178	Stress-induced decrease of central benzodiazepine receptors number is not due to internalization. Pharmacological Research, 1989, 21, 107-108.	7.1	0
179	Characterization of high affinity and stereospecific binding to rat brain. Neurochemistry International, 1988, 13, 345-351.	3.8	15
180	Different components of 3H-imipramine binding in rat brain membranes: Relation to serotonin uptake sites. Life Sciences, 1988, 42, 575-583.	4.3	12

#	Article	IF	CITATIONS
181	Effect of long term amineptine treatment on pre―and postsynaptic mechanisms in rat brain. British Journal of Pharmacology, 1986, 88, 269-275.	5.4	25
182	Localization of GABAA and GABAB receptor subtypes on serotonergic neurons. Brain Research, 1986, 371, 372-375.	2.2	24
183	Allosteric Inhibition as a Model to Explain Flatter Displacement Curves in Binding Experiments: Application to â€~Heterogeneous' Serotonin Receptors. Journal of Receptors and Signal Transduction, 1986, 6, 27-46.	1.2	2
184	In vivo interaction of premazepam with benzodiazepine receptors: Relation to its pharmacological effects. Psychopharmacology, 1985, 86, 464-467.	3.1	7
185	Effects of denzimol on benzodiazepine receptors in the CNS: Relationship between the enhancement of diazepam activity and benzodiazepine binding sites induced by denzimol in the rat. Life Sciences, 1984, 35, 1811-1820.	4.3	3
186	Stimulation of serotonin synthesis in rat brain after antiepilepsirine, an antiepileptic piperine derivative. Biochemical Pharmacology, 1984, 33, 3883-3886.	4.4	14